Brokerages Anticipate PolyOne Co. (NYSE:POL) Will Announce Quarterly Sales of $682.65 Million

Share on StockTwits

Wall Street analysts expect that PolyOne Co. (NYSE:POL) will report $682.65 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for PolyOne’s earnings, with the highest sales estimate coming in at $687.50 million and the lowest estimate coming in at $679.80 million. PolyOne reported sales of $834.00 million in the same quarter last year, which indicates a negative year over year growth rate of 18.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, February 4th.

According to Zacks, analysts expect that PolyOne will report full-year sales of $3.03 billion for the current fiscal year, with estimates ranging from $2.84 billion to $3.19 billion. For the next financial year, analysts forecast that the firm will report sales of $2.95 billion, with estimates ranging from $2.91 billion to $3.01 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow PolyOne.

PolyOne (NYSE:POL) last announced its quarterly earnings data on Tuesday, October 22nd. The specialty chemicals company reported $0.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.01. The business had revenue of $705.00 million during the quarter, compared to analysts’ expectations of $721.91 million. PolyOne had a return on equity of 30.57% and a net margin of 4.03%. The firm’s quarterly revenue was down 3.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 earnings per share.

A number of research analysts have issued reports on POL shares. Zacks Investment Research cut PolyOne from a “buy” rating to a “hold” rating in a research note on Wednesday, September 25th. Robert W. Baird upgraded PolyOne from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $30.00 to $36.00 in a research note on Monday, July 22nd. ValuEngine upgraded PolyOne from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. TheStreet upgraded PolyOne from a “c+” rating to a “b-” rating in a research note on Thursday, July 25th. Finally, Wells Fargo & Co started coverage on PolyOne in a research note on Tuesday, October 15th. They set a “market perform” rating and a $35.00 price objective for the company. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. PolyOne has an average rating of “Buy” and an average price target of $34.71.

Several hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its stake in shares of PolyOne by 0.9% in the third quarter. Oppenheimer & Co. Inc. now owns 57,525 shares of the specialty chemicals company’s stock worth $1,878,000 after purchasing an additional 500 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of PolyOne by 220.7% in the second quarter. Parallel Advisors LLC now owns 789 shares of the specialty chemicals company’s stock worth $25,000 after purchasing an additional 543 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of PolyOne by 2.3% in the third quarter. Envestnet Asset Management Inc. now owns 23,977 shares of the specialty chemicals company’s stock worth $783,000 after purchasing an additional 544 shares during the last quarter. Arizona State Retirement System raised its stake in shares of PolyOne by 1.2% in the second quarter. Arizona State Retirement System now owns 56,476 shares of the specialty chemicals company’s stock worth $1,773,000 after purchasing an additional 667 shares during the last quarter. Finally, Investors Research Corp purchased a new position in shares of PolyOne in the second quarter worth $25,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

NYSE:POL remained flat at $$33.48 during trading hours on Thursday. The company’s stock had a trading volume of 229,845 shares, compared to its average volume of 580,603. The firm has a 50-day moving average price of $32.25 and a 200-day moving average price of $30.29. The firm has a market capitalization of $2.55 billion, a PE ratio of 13.78, a P/E/G ratio of 2.06 and a beta of 1.70. PolyOne has a 1-year low of $24.47 and a 1-year high of $35.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.88 and a quick ratio of 1.43.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.203 per share. This is a boost from PolyOne’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, December 12th. This represents a $0.81 dividend on an annualized basis and a yield of 2.43%. PolyOne’s payout ratio is presently 32.10%.

PolyOne Company Profile

PolyOne Corporation provides specialized polymer materials, services, and solutions in the United States, Canada, Mexico, Europe, South America, and Asia. It operates in four segments: Color, Additives and Inks; Specialty Engineered Materials; Performance Products and Solutions; and Distribution. The Color, Additives and Inks segment offers specialized color and additive concentrates in solid and liquid form for thermoplastics; dispersions for thermosets; and specialty inks, plastisols, and vinyl slush molding solutions.

Featured Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on PolyOne (POL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PolyOne (NYSE:POL)

Receive News & Ratings for PolyOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyOne and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.